Tags · Evidence

randomised trial

Randomised controlled trial evidence.

174 topics 62 solved Group: Evidence

174 topics · page 4 of 6

Topic	Participants	Replies	Views	Activity
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove Evidence › Journal club number needed to treat risk of bias journal club effect size Second pass at: Journal club: STEP 4 and what a withdrawal design can prove Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med ,…	+81	90	54k	9mo
[2026 update] Does dual agonism explain the effect size, or is it dose? Compounds › Tirzepatide SURMOUNT programme randomised trial SURPASS programme effect size Solved Asking directly, because I could not find a straight answer: Does dual agonism explain the effect size, or is it dose? Session topic: SELECT ( N Engl J Med , 2023). Please read it before posting; the…	+58	63	40k	9mo
Journal club: indirect comparison between two programmes, defended and attacked — one year on Evidence › Journal club randomised trial risk of bias effect size estimand Posting this under the heading it deserves: Journal club: indirect comparison between two programmes, defended and attacked — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N…	+45	50	3k	9mo
Semaglutide versus liraglutide head to head: reading STEP 8 carefully Compounds › Semaglutide STEP programme SELECT trial randomised trial type 2 diabetes Under review On the subject in the title: Semaglutide versus liraglutide head to head: reading STEP 8 carefully Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a…	+72	81	1.5k	9mo
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Compounds › Tirzepatide SURMOUNT programme randomised trial tirzepatide SURPASS programme Solved Closed Posting this under the heading it deserves: SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med…	+122	136	48k	9mo
What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version Compounds › Tirzepatide SURMOUNT programme randomised trial effect size tirzepatide Solved Asking directly, because I could not find a straight answer: What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version Comparing PIONEER 6 ( N Engl J Med ,…	+48	52	609	10mo
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on Compounds › Retatrutide retatrutide preprint randomised trial Solved Closed The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on I will give what I have already checked below so nobody repeats it. Comparing STEP 4 (…		4	3.7k	10mo
Trial registration and comparing the protocol with the paper Evidence › Trials randomised trial open label intention to treat Trial registration and comparing the protocol with the paper — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim I do…	+38	44	4.8k	10mo
Comparing tirzepatide and semaglutide is harder than the tables suggest Compounds › Tirzepatide SURMOUNT programme randomised trial effect size Posting this under the heading it deserves: Comparing tirzepatide and semaglutide is harder than the tables suggest Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with STEP…		2	3.8k	10mo
Cagrilintide's dosing interval and the pharmacokinetics behind it Compounds › Cagrilintide & amylin analogues effect size randomised trial amylin analogues cagrisema Solved Cagrilintide's dosing interval and the pharmacokinetics behind it — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SELECT ( N Engl J Med ,…	+98	105	24k	10mo
Second pass at: Triple agonism: additive, synergistic, or neither? Compounds › Retatrutide TRIUMPH programme effect size retatrutide randomised trial Solved Under review Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen STEP 8 ( JAMA , 2022) cited in support…	+114	120	1.4k	10mo
Journal club: STEP-HFpEF and symptom endpoints — a second dataset Evidence › Journal club estimand risk of bias randomised trial journal club On the subject in the title: Journal club: STEP-HFpEF and symptom endpoints — a second dataset Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with STEP 4 ( JAMA , 2021) and…	+11	15	4k	10mo
Why fasting instructions for oral semaglutide are not optional advice — does this still hold? Compounds › Oral incretins orforglipron SOUL trial PIONEER programme randomised trial Solved Asking directly, because I could not find a straight answer: Why fasting instructions for oral semaglutide are not optional advice — does this still hold? Session topic: PIONEER 6 ( N Engl J Med , 2019).…	+98	106	3.1k	10mo
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how confident we can be Compounds › Tirzepatide SURPASS programme randomised trial effect size Under review The question in the title: What the GIP component of tirzepatide is thought to contribute, and how confident we can be I will give what I have already checked below so nobody repeats it. Comparing STEP 4 (…	+109	124	31k	10mo
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question Evidence › Journal club randomised trial risk of bias effect size number needed to treat Posting this under the heading it deserves: Journal club: orforglipron phase 2 and the non-peptide question Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024). Please read it…	+80	91	10k	11mo
Coming back to: Sample size calculations, read backwards from the published number Evidence › Trials estimand discontinuation & dropout surrogate endpoints randomised trial On the subject in the title: Sample size calculations, read backwards from the published number Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…	+82	88	1.8k	11mo
[2026 update] What we do not know about retatrutide, listed explicitly Compounds › Retatrutide TRIUMPH programme preprint effect size randomised trial Wiki What we do not know about retatrutide, listed explicitly — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N Engl J Med , 2015) with STEP 2 ( Lancet ,…	+79	83	952	11mo
Journal club: STEP-HFpEF and symptom endpoints Evidence › Journal club journal club effect size estimand risk of bias Journal club: STEP-HFpEF and symptom endpoints — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-1 ( N Engl J Med , 2022) and finding…	+18	22	2.5k	11mo
The CagriSema phase 2 paper and what a fixed combination buys Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide effect size Posting this under the heading it deserves: The CagriSema phase 2 paper and what a fixed combination buys Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in…	+88	93	29k	11mo
SURMOUNT-4 and what withdrawal data does and does not tell an individual Compounds › Tirzepatide SURPASS programme randomised trial effect size SURMOUNT programme Solved SURMOUNT-4 and what withdrawal data does and does not tell an individual — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 8 ( JAMA , 2022)…		4	42k	11mo
Comparing the STEP programme populations: who was actually enrolled — the long version Compounds › Semaglutide STEP programme randomised trial type 2 diabetes On the subject in the title: Comparing the STEP programme populations: who was actually enrolled — the long version Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with…		4	7.7k	11mo
Tirzepatide molecular mass and the charge states you would expect on ESI Compounds › Tirzepatide effect size SURPASS programme SURMOUNT programme randomised trial Tirzepatide molecular mass and the charge states you would expect on ESI Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited…	+36	40	44k	11mo
[2026 update] Journal club: is percentage weight change the right endpoint? Evidence › Journal club effect size risk of bias randomised trial Journal club: is percentage weight change the right endpoint? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 ( N Engl J Med , 2021) with…	+105	118	18k	11mo
Reading a combination trial: attributing effect to components Compounds › Cagrilintide & amylin analogues cagrisema amylin analogues effect size cagrilintide Closed On the subject in the title: Reading a combination trial: attributing effect to components Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…		4	19k	11mo
[2026 update] Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA Compounds › Tirzepatide tirzepatide effect size randomised trial Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think…		2	58k	11mo
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly Compounds › Tirzepatide tirzepatide SURPASS programme randomised trial effect size Solved Closed Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 2 ( Lancet ,…	+150	163	22k	11mo
Journal club: how we handle discontinuation in obesity trials Evidence › Journal club randomised trial effect size number needed to treat Solved Closed On the subject in the title: Journal club: how we handle discontinuation in obesity trials Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…		2	1.9k	12mo
Comparators chosen for regulatory reasons rather than clinical ones — one year on Evidence › Trials randomised trial intention to treat open label estimand Solved Comparators chosen for regulatory reasons rather than clinical ones — one year on — setting out what I have, and where I think it stops being reliable. Session topic: SURMOUNT-2 ( Lancet , 2023). Please read…	+82	87	1.1k	12mo
Cagrilintide molecular characteristics and analytical considerations Compounds › Cagrilintide & amylin analogues cagrilintide randomised trial amylin analogues cagrisema Cagrilintide molecular characteristics and analytical considerations — setting out what I have, and where I think it stops being reliable. I have seen SURMOUNT-2 ( Lancet , 2023) cited in support of a claim I…		4	41k	12mo
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1 Compounds › Cagrilintide & amylin analogues cagrisema effect size randomised trial cagrilintide On the subject in the title: Amylin analogue mechanism: satiety signalling separate from GLP-1 Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I…	+27	31	671	12mo